| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10010162 | HBV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS10043039 | HBV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS30079405 | HIV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS30086094 | HIV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS20006710 | HPV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS20052673 | HPV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS20026978 | HPV | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS44017912 | HTLV-1 | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS44029752 | HTLV-1 | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
| TVIS44029763 | HTLV-1 | ENSG00000087245.13 | protein_coding | MMP2 | No | No | 4313 | P08253 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MMP2 |
|---|---|
| DrugBank ID | DB01197 |
| Drug Name | Captopril |
| Target ID | BE0000642 |
| UniProt ID | P08253 |
| Regulation Type | inhibitor |
| PubMed IDs | 17308006; 19057128; 10328230; 12381651; 15993560; 20184869 |
| Citations | Brower GL, Levick SP, Janicki JS: Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. Epub 2007 Feb 16.@@Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5.@@Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999 May 31;81(5):761-6.@@Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30.@@Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1.@@Yamamoto D, Takai S, Hirahara I, Kusano E: Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010 May 2;411(9-10):762-4. doi: 10.1016/j.cca.2010.02.059. Epub 2010 Feb 22. |
| Groups | Approved |
| Direct Classification | Proline and derivatives |
| SMILES | C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O |
| Pathways | Captopril Action Pathway |
| PharmGKB | PA448780 |
| ChEMBL | CHEMBL1560 |
